Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantation

被引:47
作者
Peccatori, J
Barkholt, L
Demirer, T
Sormani, MP
Bruzzi, P
Ciceri, F
Zambelli, A
Da Prada, GA
Pedrazzoli, P
Siena, S
Massenkeil, G
Martino, R
Lenhoff, S
Corradini, P
Rosti, G
Ringden, O
Bregni, M
Niederwieser, D
机构
[1] Ist Sci San Raffaele, Bone Marrow Transplantat Unit, Milan, Italy
[2] Huddinge Univ Hosp, Dept Hematol, S-14186 Huddinge, Sweden
[3] Ankara Univ, Stem Cell Transplantat Unit, TR-06100 Ankara, Turkey
[4] Natl Inst Canc Res, Dept Epidemiol, Genoa, Italy
[5] Fdn S Maugeri, Dept Med Oncol, Pavia, Italy
[6] Oped Niguarda Granda, Dept Med Oncol, Milan, Italy
[7] Charit, Dept Hematol Oncol, Berlin, Germany
[8] Hosp Santa Creu & San Paul, Dept Hematol, Barcelona, Spain
[9] Univ Lund Hosp, Dept Hematol, S-22185 Lund, Sweden
[10] Ist Nazl Tumori, Dept Hematol, I-20133 Milan, Italy
[11] Osped Civile, Dept Med Oncol, Ravenna, Italy
[12] Univ Leipzig, Dept Hematol Oncol, D-7010 Leipzig, Germany
关键词
C-reactive protein; renal cell carcinoma; allogeneic stem cell transplantation; prognostic factors;
D O I
10.1002/cncr.21477
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. The objective of this study was to identify prognostic factors for predicting survival in patients with advanced renal cell carcinoma (RCC) who had undergone an allogeneic stem cell transplantation after failure on immunotherapy. METHODS. The authors Studied 70 patients with advanced RCC Who underwent allogeneic transplantation with a fludarabine-based, reduced-intensity regimen. Ten parameters were analyzed at the time of transplantation for their power to predict Survival. Clinical features were examined first univariately; then, variables that were correlated significantly with Survival in the univariate analysis were included in a multivariate Cox regression model. RESULTS. Factors that were found to be associated significantly with limited survival were performance Status, the number of metastatic sites, the presence of mediastinal metastasis, hemoglobin level, C-reactive protein (CRP) level, lactate dehydrogenase (LDH) level, and neutrophil counts. All these variables were included in a multivariate Cox regression model, and three were retained in the final model. Patients were classified according to the score estimated by the final Cox model in two groups (above or below the median Value): The median Survival was 3.5 months for patients who had a poor prognosis patients versus 23 months for patients who had a good prognosis. CONCLUSIONS. The Current findings suggested that three easily available parameters (performance status, CRP level, and LDH level) could be used to stratify patients with advanced RCC who are candidates for allografting and to assist clinicians in decision-making and selection of an appropriate treatment program. (c) 2005 American Cancer Society.
引用
收藏
页码:2099 / 2103
页数:5
相关论文
共 9 条
[1]   Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer [J].
Bregni, M ;
Dodero, A ;
Peccatori, J ;
Pescarollo, A ;
Bernardi, M ;
Sassi, I ;
Voena, C ;
Zaniboni, A ;
Bordignon, C ;
Corradini, P .
BLOOD, 2002, 99 (11) :4234-4236
[2]   Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation [J].
Childs, R ;
Chernoff, A ;
Contentin, N ;
Bahceci, E ;
Schrump, D ;
Leitman, S ;
Read, EJ ;
Tisdale, J ;
Dunbar, C ;
Linehan, WM ;
Young, NS ;
Barrett, AJ ;
Clave, E ;
Epperson, D ;
Mayo, V .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (11) :750-758
[3]  
Gooley TA, 1999, STAT MED, V18, P695, DOI 10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO
[4]  
2-O
[5]   Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma - A stratification tool for prospective clinical trials [J].
Leibovich, BC ;
Han, KR ;
Bui, MHT ;
Pantuck, AJ ;
Dorey, FJ ;
Figlin, RA ;
Belldegrun, A .
CANCER, 2003, 98 (12) :2566-2575
[6]   Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma [J].
Motzer, RJ ;
Mazumdar, M ;
Bacik, J ;
Berg, W ;
Amsterdam, A ;
Ferrara, J .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (08) :2530-2540
[7]   Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma [J].
Motzer, RJ ;
Bacik, J ;
Schwartz, LH ;
Reuter, V ;
Russo, P ;
Marion, S ;
Mazumdar, M .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (03) :454-463
[8]   Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines:: a report from the Groupe Francais d'Immunotherapie [J].
Négrier, S ;
Escudier, B ;
Gomez, F ;
Douillard, JY ;
Ravaud, A ;
Chevreau, C ;
Buclon, M ;
Pérol, D ;
Lasset, C .
ANNALS OF ONCOLOGY, 2002, 13 (09) :1460-1468
[9]   Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen - A pilot study in patients with refractory malignancies [J].
Pedrazzoli, P ;
Da Prada, GA ;
Giorgiani, G ;
Schiavo, R ;
Zambelli, A ;
Giraldi, E ;
Landonio, G ;
Locatelli, F ;
Siena, S ;
Della Cuna, GR .
CANCER, 2002, 94 (09) :2409-2415